secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0000950170-23-010758
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics Q4 2022 net loss $5.1M; cash runway extended into Q2 2024
-----------------------------------------------------------------------------

- Net loss of $5.1M for Q4 2022 vs net income of $1.6M in Q4 2021; full-year net loss $18.8M vs $36.1M in 2021.
- Cash and cash equivalents $70.1M as of Dec 31, 2022; expects runway into Q2 2024.
- Phase 3 prostate cancer trial topline data expected Q4 2024; phase 2 NSCLC data expected Q3 2023.
- Paused enrollment in phase 2 pancreatic cancer trial subject to additional funding; initial data still expected Q4 2023.
- CAN-3110 in recurrent HGG showed median overall survival of 11.6 months in phase 1 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023010758/0000950170-23-010758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017023010758/cadl-20230330.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer